Nucleic acid detection using type iii crispr complex
AssigneeMontana State University
InventorsBlake A. WIEDENHEFT, Andrew SANTIAGO-FRANGOS, Anna A. NEMUDRAIA, Artem A. NEMUDRYI
Life of this patent
Estimating the term…
Loading patent…
AssigneeMontana State University
InventorsBlake A. WIEDENHEFT, Andrew SANTIAGO-FRANGOS, Anna A. NEMUDRAIA, Artem A. NEMUDRYI
Estimating the term…
The disclosure relates to engineered systems and methods for detecting target nucleic acid in a sample, which may be a complex mixture. The systems and methods may improve sensitivity of target nucleic acid detection by enhancing signal generation. For example, signal generation may be enhanced through programmable capture and concentration of the target nucleic acid using an engineered type III CRISPR complex. Various ancillary nucleases such as Can1, Can2, and NucC are identified and may be used for detection. For example, binding of the engineered type III CRISPR complex may produce products that activate the identified ancillary nucleases. Different activators trigger changes in the substrate specificity of these nucleases. The activated nucleases may be used to detect programmatic detection of the target nucleic in the sample. The systems and methods are shown to detect viral RNA directly from nasopharyngeal swab samples.
A method of programmatically capturing and detecting target nucleic acid in a sample based on an engineered type III Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) complex, the method comprising:
Dependencies are inferred from the claim text.